Trial · NCT01285557
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Overall Survival (OS) | S-1+Cisplatin | 7.5 | 95% Confidence Interval 6.7 to 9.3 | months | |
| Overall Survival (OS) | 5FU+Cisplatin | 6.6 | 95% Confidence Interval 5.7 to 8.1 | months | |
| Progression-free Survival (PFS) | S-1+Cisplatin | 4.4 | 95% Confidence Interval 3.8 to 5.6 | months | |
| Progression-free Survival (PFS) | 5FU+Cisplatin | 3.9 | 95% Confidence Interval 3.6 to 5.2 | months | |
| Time to Treatment Failure (TTF) | S-1+Cisplatin | 4.2 | 95% Confidence Interval 3.8 to 4.9 | months | |
| Time to Treatment Failure (TTF) | 5FU+Cisplatin | 3.8 | 95% Confidence Interval 3.4 to 4.3 | months | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE) | S-1+Cisplatin | TEAE | 214 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE) | 5FU+Cisplatin | TEAE | 111 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE) | S-1+Cisplatin | TESAE | 63 | Participants | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAE) | 5FU+Cisplatin | TESAE | 31 | Participants | |
| Number of Participants With TEAEs With Severity Greater Than or Equal to (>=) Grade 3 | S-1+Cisplatin | 157 | Participants | ||
| Number of Participants With TEAEs With Severity Greater Than or Equal to (>=) Grade 3 | 5FU+Cisplatin | 78 | Participants | ||
| Overall Response Rate (ORR): Percentage of Participants With Overall Response | S-1+Cisplatin | 34.7 | 95% Confidence Interval 28.0 to 41.9 | percentage of participants | |
| Overall Response Rate (ORR): Percentage of Participants With Overall Response | 5FU+Cisplatin | 19.8 | 95% Confidence Interval 12.2 to 29.4 | percentage of participants | |
| Duration of Response (DR) | S-1+Cisplatin | 5.1 | 95% Confidence Interval 3.0 to 5.8 | months | |
| Duration of Response (DR) | 5FU+Cisplatin | 4.2 | 95% Confidence Interval 2.0 to 6.0 | months | |
| Time to Tumor Response (TTR) | S-1+Cisplatin | 1.8 | 95% Confidence Interval 1.8 to 1.9 | months | |
| Time to Tumor Response (TTR) | 5FU+Cisplatin | 1.9 | 95% Confidence Interval 1.8 to 2.1 | months |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01285557/results